Cite
HARVARD Citation
Zammarrelli, W. et al. (n.d.). EP159/#428 Real-world experience and common adverse events when using combination lenvatinib and pembrolizumab for the treatment of recurrent uterine cancer. International journal of gynecological cancer. pp. A111-A112. [Online].